文献速递头颈部肿瘤放疗姑息放疗与转移瘤

局部区域放疗在初诊转移性鼻咽癌接受化疗-免疫治疗患者中的疗效:一项多中心倾向性评分匹配研究

Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
PubMed 文献 · Radiother Oncol · 2024-12-19

本研究纳入四中心546例初诊转移性鼻咽癌患者,比较接受铂类化疗-免疫治疗联合或不联合局部区域放疗的疗效。倾向性评分匹配后,LRRT并非独立预后因素(HR 1.25,95%CI 0.92-1.69,p=0.156);亚组分析显示寡转移和EBV DNA2-6周期不可测患者可从LRRT获得PFS显著获益。

要点

  • 匹配队列中LRRT非独立预后因素(HR 1.25,95%CI 0.92-1.69,p=0.156)。
  • 寡转移患者接受LRRT的3年PFS率70.6% vs 49.3%(p=0.043)。
  • EBV DNA2-6周期不可测者接受LRRT的3年PFS率57.9% vs 43.4%(p=0.043)。

核心结论

  • LRRT可延长M1-NPC患者的无进展生存期。
  • 寡转移和EBV DNA2-6周期不可测是筛选LRRT获益人群的潜在指标。

研究设计与样本

  • 多中心倾向性评分匹配研究,纳入四中心接受铂类化疗-免疫治疗联合或不联合LRRT的M1-NPC患者。
  • 共纳入546例初诊转移性鼻咽癌患者,非LRRT组140例,LRRT组406例;倾向性评分匹配后LRRT组244例,非LRRT组122例。

主要发现

  • LRRT组3年PFS率53.2% vs 非LRRT组31.2%(p<0.001)。
  • 匹配队列多因素分析显示LRRT非独立预后因素(HR 1.25,95%CI 0.92-1.69,p=0.156)。
  • 匹配队列亚组分析:寡转移患者接受LRRT的3年PFS率70.6% vs 49.3%(p=0.043)。
  • 匹配队列亚组分析:多转移患者接受LRRT的3年PFS率35.8% vs 27.8%(p=0.17)。
  • 匹配队列亚组分析:EBV DNA2-6周期不可测者接受LRRT的3年PFS率57.9% vs 43.4%(p=0.043);可测者16.2% vs 20.3%(p=0.21)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the efficacy of local-regional radiotherapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (dm NPC) patients receiving chemo-immunotherapy as first-line treatment and select the beneficiaries from LRRT. METHODS AND MATERIALS: M1-NPC patients receiving platinum-based chemo-immunotherapy with or without LRRT from four centers were included in this study. The propensity score matching (PSM) analysis was employed to balance the baseline characteristics between the LRRT and non-LRRT groups. RESULTS: 546 dm NPC patients (140 patients in the non-LRRT group and 406 patients in the LRRT group) were incorporated. Patients receiving LRRT demonstrated significantly improved progression-free survival (3-year PFS rate, 53.2 % vs 31.2 %, p < 0.001). After PSM analysis, there were 244 patients in the LRRT group and 122 patients in the non-LRRT group. Multivariable analysis indicated that LRRT was not an independent prognostic factor in the matched cohort (HR, 1.25, 95 % CI, 0.92-1.69, p = 0.156). Subgroup analysis among the matched cohort showed a significant increase in PFS for patients with oligo metastatic disease (OMD) who received LRRT (3-year PFS rate, 70.6 % vs 49.3 %, p = 0.043). In contrast, no such benefit was observed in patients with poly metastatic disease (PMD, 3-year PFS rate, 35.8 % vs 27.8 %, p = 0.17). Furthermore, LRRT significantly enhanced survival in patients with undetectable EBV DNA2-6 cycles (3-year PFS rate, 57.9 % vs. 43.4 %, p = 0.043), whereas no survival improvement was noted in patients with detectable EBV DNA2-6 cycles (16.2 % vs. 20.3 %, p = 0.21). CONCLUSION: LRRT could prolong PFS in M1-NPC patients. OMD and undetectable EBV DNA2-6 cycles are potential indicators for selecting beneficiaries from LRRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. He SQ, Liu GY, Yu YH, et al. Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study. Radiother Oncol. 2024. PMID: 39709030. doi:10.1016/j.radonc.2024.110687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。